Yuhan Corporation (000105.KS)
KRW 101900.0
(-3.04%)
KRW 101900.0
(-3.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 74.56 Billion KRW | -46.77% |
| 2022 | 106.45 Billion KRW | -23.98% |
| 2021 | 140.03 Billion KRW | 5.89% |
| 2020 | 132.23 Billion KRW | 105.71% |
| 2019 | 64.28 Billion KRW | 28.25% |
| 2018 | 50.12 Billion KRW | -43.49% |
| 2017 | 88.7 Billion KRW | -9.29% |
| 2016 | 97.79 Billion KRW | 13.93% |
| 2015 | 85.83 Billion KRW | 15.38% |
| 2014 | 74.39 Billion KRW | 20.3% |
| 2013 | 61.83 Billion KRW | 78.73% |
| 2012 | 34.59 Billion KRW | -29.44% |
| 2011 | 49.03 Billion KRW | -40.67% |
| 2010 | 82.64 Billion KRW | -4.29% |
| 2009 | 86.35 Billion KRW | 4.07% |
| 2008 | 82.97 Billion KRW | 15.83% |
| 2007 | 71.63 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 18.54 Billion KRW | 3112.82% |
| 2024 Q1 | 577.13 Million KRW | -90.34% |
| 2023 Q4 | 5.97 Billion KRW | 576.4% |
| 2023 FY | 56.67 Billion KRW | -46.77% |
| 2023 Q1 | 43.54 Billion KRW | 470.0% |
| 2023 Q2 | 27.29 Billion KRW | -37.32% |
| 2023 Q3 | 883.25 Million KRW | -96.76% |
| 2022 FY | 106.45 Billion KRW | -23.98% |
| 2022 Q2 | 46.36 Billion KRW | 56.5% |
| 2022 Q1 | 29.62 Billion KRW | 523.45% |
| 2022 Q4 | 7.64 Billion KRW | -66.52% |
| 2022 Q3 | 22.82 Billion KRW | -50.78% |
| 2021 Q1 | 13.9 Billion KRW | -48.81% |
| 2021 Q2 | 23.42 Billion KRW | 68.53% |
| 2021 FY | 140.03 Billion KRW | 5.89% |
| 2021 Q3 | 6.51 Billion KRW | -72.19% |
| 2021 Q4 | 4.75 Billion KRW | -27.07% |
| 2020 Q1 | 1.07 Billion KRW | -87.39% |
| 2020 Q3 | 20.37 Billion KRW | -42.87% |
| 2020 Q4 | 27.15 Billion KRW | 33.29% |
| 2020 FY | 132.23 Billion KRW | 105.71% |
| 2020 Q2 | 35.65 Billion KRW | 3221.0% |
| 2019 Q4 | 8.51 Billion KRW | 154.59% |
| 2019 Q2 | -5.41 Billion KRW | -188.93% |
| 2019 Q1 | 6.08 Billion KRW | -20.91% |
| 2019 FY | 64.28 Billion KRW | 28.25% |
| 2019 Q3 | 3.34 Billion KRW | 161.77% |
| 2018 Q2 | 16.61 Billion KRW | -35.28% |
| 2018 FY | 50.12 Billion KRW | -43.49% |
| 2018 Q4 | 7.7 Billion KRW | 4973.1% |
| 2018 Q3 | 151.78 Million KRW | -99.09% |
| 2018 Q1 | 25.66 Billion KRW | 144.92% |
| 2017 Q4 | 10.47 Billion KRW | -52.31% |
| 2017 FY | 88.7 Billion KRW | -9.29% |
| 2017 Q1 | 35.51 Billion KRW | 26.73% |
| 2017 Q2 | 20.74 Billion KRW | -41.6% |
| 2017 Q3 | 21.97 Billion KRW | 5.93% |
| 2016 Q1 | 19.9 Billion KRW | 46.72% |
| 2016 Q2 | 24.62 Billion KRW | 23.7% |
| 2016 Q3 | 25.23 Billion KRW | 2.49% |
| 2016 FY | 97.79 Billion KRW | 13.93% |
| 2016 Q4 | 28.02 Billion KRW | 11.05% |
| 2015 Q3 | 31.7 Billion KRW | 23.65% |
| 2015 Q4 | 13.56 Billion KRW | -57.21% |
| 2015 FY | 85.83 Billion KRW | 15.38% |
| 2015 Q1 | 14.91 Billion KRW | -36.72% |
| 2015 Q2 | 25.64 Billion KRW | 71.88% |
| 2014 Q1 | 13.74 Billion KRW | -35.01% |
| 2014 FY | 74.39 Billion KRW | 20.3% |
| 2014 Q4 | 23.57 Billion KRW | 35.04% |
| 2014 Q3 | 17.45 Billion KRW | -11.03% |
| 2014 Q2 | 19.62 Billion KRW | 42.78% |
| 2013 Q3 | 11.41 Billion KRW | -26.72% |
| 2013 Q4 | 21.14 Billion KRW | 85.21% |
| 2013 FY | 61.83 Billion KRW | 78.73% |
| 2013 Q1 | 13.7 Billion KRW | 57.91% |
| 2013 Q2 | 15.57 Billion KRW | 13.66% |
| 2012 Q2 | 11.28 Billion KRW | 40.43% |
| 2012 Q1 | 8.03 Billion KRW | 0.0% |
| 2012 Q3 | 4.43 Billion KRW | -60.72% |
| 2012 Q4 | 8.67 Billion KRW | 95.85% |
| 2012 FY | 34.59 Billion KRW | -29.44% |
| 2011 Q1 | 17.13 Billion KRW | -36.62% |
| 2011 FY | 49.03 Billion KRW | -40.67% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 15.88 Billion KRW | -7.66% |
| 2011 Q2 | 17.2 Billion KRW | 0.37% |
| 2010 Q3 | 17.63 Billion KRW | -31.1% |
| 2010 Q2 | 25.59 Billion KRW | 9.31% |
| 2010 Q1 | 23.41 Billion KRW | -18.64% |
| 2010 Q4 | 27.03 Billion KRW | 53.32% |
| 2010 FY | 82.64 Billion KRW | -4.29% |
| 2009 Q3 | 19.66 Billion KRW | -7.05% |
| 2009 Q4 | 28.78 Billion KRW | 46.37% |
| 2009 FY | 86.35 Billion KRW | 4.07% |
| 2009 Q1 | 18.97 Billion KRW | -16.54% |
| 2009 Q2 | 21.15 Billion KRW | 11.5% |
| 2008 Q4 | 22.73 Billion KRW | 23.96% |
| 2008 FY | 82.97 Billion KRW | 15.83% |
| 2008 Q1 | 18.3 Billion KRW | 19.24% |
| 2008 Q2 | 21.72 Billion KRW | 18.68% |
| 2008 Q3 | 18.33 Billion KRW | -15.57% |
| 2007 FY | 71.63 Billion KRW | 0.0% |
| 2007 Q1 | 13.15 Billion KRW | 0.0% |
| 2007 Q2 | 21.49 Billion KRW | 63.37% |
| 2007 Q3 | 15.51 Billion KRW | -27.84% |
| 2007 Q4 | 15.34 Billion KRW | -1.06% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -20354.037% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 3.017% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 193.717% |
| HANDOK Inc. | 12.57 Billion KRW | -492.762% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 3848.477% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -567.02% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 513.26% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 66.844% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -2339.827% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -419.584% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -12402.047% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -7636.588% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -175.836% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -20354.037% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 1061.347% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -1748.523% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 206.594% |
| JW Holdings Corporation | 143.66 Billion KRW | 48.1% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 239.584% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 69.764% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 25.663% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 257.33% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -976.416% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -1052.252% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -753.961% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -20354.037% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -52.893% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 44.109% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 25.663% |
| Yuhan Corporation | 74.56 Billion KRW | 0.0% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -256.414% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -2291.823% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -73.422% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 25.663% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -263.998% |
| Korea United Pharm Inc. | 54.94 Billion KRW | -35.692% |
| CKD Bio Corp. | -20.15 Billion KRW | 469.991% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -131.325% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -194.689% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -129.246% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 257.33% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -124.946% |
| Boryung Corporation | 68.26 Billion KRW | -9.222% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 298.851% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -419.584% |
| JW Lifescience Corporation | 32.09 Billion KRW | -132.344% |